February 6, 2023
Lung Cancer Initiative awards Pecot $100,000 grant
The grant supports Chad Pecot, MD, and his research into the mechanistic and therapeutic implications of co-targeting two genes linked to lung cancer.
February 6, 2023
The grant supports Chad Pecot, MD, and his research into the mechanistic and therapeutic implications of co-targeting two genes linked to lung cancer.
January 25, 2023
Shawn Hingtgen, PhD, and his lab team have developed a method they call a “slice platform” that may help clinicians choose the best treatment for their brain tumor patients.
January 9, 2023
Brian Jensen, MD, sees cancer patients who have developed, or are at risk of developing, heart damage in response to their chemotherapy regimens.
December 15, 2022
Lindsey James, PhD, is well-suited to the collaborative relationship between UNC Lineberger and UNC Eshelman School of Pharmacy, taking her interests in medicinal chemistry and epigenetics and working with cancer center physicians and researchers to make strides into cancer care and treatment.
December 9, 2022
UNC Lineberger researchers will present the latest findings from studies and lead educational sessions at the 64th American Society of Hematology Annual Meeting in New Orleans, Dec. 10-13.
November 18, 2022
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2022 Highly Cited Researchers list.
July 22, 2022
The UNC RNA Discovery Center, led by Chad Pecot, MD, will cultivate an inclusive community of scientists dedicated to investigating all aspects of RNA biology.
March 24, 2022
Yevgeny Brudno, PhD, and colleagues from NC State University and UNC-Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T for attacking cancerous tumors.
January 31, 2022
Four UNC Lineberger members have been elected 2021 fellows of the American Association for the Advancement of Science, one of the most distinct honors in the scientific community.
September 25, 2020
New research by Chad Pecot, MD, and colleagues shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer.